TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06460402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice packing
Description: For both arms, participants will self-administer interventions at home per instructions: ice packs every 2 hours for 48 hours (ice pack arm) or sitz baths 2-3 times daily for 7 days (warm water arm). Standardized supplies and daily logs will be provided. All participants receive standard postop care with analgesics and wound care. Adverse events will be monitored closely. Intervention duration: 48 hours (ice), 7 days (sitz bath). Assessments: baseline, 24/48/72 hours (pain, swelling), 1 week (wound separation). Total study duration per participant: \~1 week from surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm sitz bath
Description: Participants in this arm will receive standard instructions to perform warm water sitz baths at home, starting from the day of surgery and continuing for 7 days postoperatively. They will be advised to take 2-3 sitz baths per day, with each bath lasting for 15-20 minutes. A standard plastic sitz bath basin will be provided to the participants, along with a thermometer to monitor the water temperature. The recommended water temperature range for the sitz baths is 37-40°C (98.6-104°F). Participants will be instructed to keep a daily log recording the number of sitz baths taken, the duration of each bath, and the water temperature. Proper hygiene and wound care instructions will also be provided to prevent infection.
Study: NCT06307821

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The intervention lasts for 12 weeks, with follow-ups conducted at weeks 0, 6, and 12 to assess participants' digestion and absorption rates of dietary protein, as well as to collect fecal samples for analysis of changes in the gut microbiota.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: The intervention lasts for 12 weeks, with follow-ups conducted at weeks 0, 6, and 12 to assess participants' digestion and absorption rates of dietary protein, as well as to collect fecal samples for analysis of changes in the gut microbiota.
Study: NCT06072326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: 200 mg/day as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: 200 mg/day as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: 200 mg/day as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: 200 mg/day as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: 200 mg/day as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: 200 mg/day as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: 2.5 mg/day as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: 2.5 mg/day as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: 2.5 mg/day as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: 2.5 mg/day as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: 2.5 mg/day as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: 2.5 mg/day as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan and Sotagliflozin
Description: 2.5 mg/day Ambrisentan as a tablet in combination with 200 mg/day Sotagliflozin as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan and Sotagliflozin
Description: 2.5 mg/day Ambrisentan as a tablet in combination with 200 mg/day Sotagliflozin as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan and Sotagliflozin
Description: 2.5 mg/day Ambrisentan as a tablet in combination with 200 mg/day Sotagliflozin as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan and Sotagliflozin
Description: 2.5 mg/day Ambrisentan as a tablet in combination with 200 mg/day Sotagliflozin as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan and Sotagliflozin
Description: 2.5 mg/day Ambrisentan as a tablet in combination with 200 mg/day Sotagliflozin as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan and Sotagliflozin
Description: 2.5 mg/day Ambrisentan as a tablet in combination with 200 mg/day Sotagliflozin as a tablet
Study: NCT04981470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: baroloop System
Description: vagal nerve stimulation
Study: NCT05005806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acid
Description: omega 3 fatty acid soft gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo soft gel
Study: NCT05750875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine
Description: Participants were given loratadine 10mg, oral, daily, for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Participants were given gabapentin 100mg, oral, daily, for 4 weeks
Study: NCT05357690

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Ultrasound guided injection into the stellate ganglion performed in the right side of the neck in a sterile fashion.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Stellate ganglion block
Description: Ultrasound guided injection into the stellate ganglion performed in the right side of the neck in a sterile fashion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 10 mL of 0.5% without epinephrine injected in the plane of the right stellate ganglion

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: 10 mL of saline injected in the plane of the right stellate ganglion
Study: NCT01722175

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ALPPS surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVO surgery
Study: NCT04712721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FF58
Description: Single intravenous radiolabeled gallium FF58 injection determined by body weight (3 Megabecquerel (MBq)/Kg (+/- 10%)). Administered dose must not be lower than 150 MBq or higher than 250 MBq.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FF58
Description: Single intravenous radiolabeled gallium FF58 injection determined by body weight (3 Megabecquerel (MBq)/Kg (+/- 10%)). Administered dose must not be lower than 150 MBq or higher than 250 MBq.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FF58
Description: Single intravenous radiolabeled gallium FF58 injection determined by body weight (3 Megabecquerel (MBq)/Kg (+/- 10%)). Administered dose must not be lower than 150 MBq or higher than 250 MBq.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FF58
Description: Single intravenous radiolabeled gallium FF58 injection determined by body weight (3 Megabecquerel (MBq)/Kg (+/- 10%)). Administered dose must not be lower than 150 MBq or higher than 250 MBq.
Study: NCT05142475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
Study: NCT04973436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioral Therapy Skills Training
Description: LiveWell: Dialectical behavioral therapy skills training adapted for patients with metastatic lung cancer
Study: NCT06281470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 Single Dose(6g)
Description: WS016 6g, to be administered orally as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 Single Dose(12g)
Description: WS016 12g, to be administered orally as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 Single Dose(24g)
Description: WS016 24g, to be administered orally as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 Single Dose(36g)
Description: WS016 36g, to be administered orally as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 Single Dose(48g)
Description: WS016 48g, to be administered orally as a single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAD matching placebo
Description: Matching placebo, to be administered orally as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 Multiple Dose(12g)
Description: WS016 12g, to be administered orally once daily for a consecutive period of 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 Multiple Dose(24g)
Description: WS016 24g, to be administered orally once daily for a consecutive period of 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 Multiple Dose(48g)
Description: WS016 48g, to be administered orally once daily for a consecutive period of 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MAD matching placebo
Description: Matching placebo, to be administered orally once daily for a consecutive period of 7 days.
Study: NCT05776121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZB001 for injection
Description: Dose Cohort1 (3 mg/kg) ZB001 four IV injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZB001 for injection
Description: Dose Cohort2 (10 mg/kg) ZB001 four IV injections
Study: NCT06098612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C11-SY08
Description: a PET imaging agent
Study: NCT05623579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: 8 Sessions of different pain education interventions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 12 Sessions of Aerobic Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 Sessions of Aerobic Exercise
Study: NCT05275374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP-102
Description: XP-102 will be administered orally once or twice daily in a continuous regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP-102
Description: XP-102 will be administered orally once or twice daily in a continuous regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP-102
Description: XP-102 will be administered orally once or twice daily in a continuous regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be administered 2mg orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be administered 2mg orally once a day.
Study: NCT04931784

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate
Description: Administration of intra-coronary nitrate before percutaneous coronary intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate
Description: Administration of intra-coronary nitrate before percutaneous coronary intervention
Study: NCT05486559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECMO-free protocol
Description: All patients randomized to the ECMO-Free Protocol Group will receive a protocolized daily assessment of readiness for liberation from VV-ECMO, which will be initiated between 6:00 AM local time and 10:00 AM local time. If the patient is enrolled after 10:00 AM local time the ECMO-free protocol will begin the following calendar day.~The ECMO-Free Protocol is a 3-step process of assessing readiness for liberation from VV-ECMO: a safety screen (Phase 1: ECMO-Free Safety Screen), titration of the non-ECMO fraction of inspired oxygen (Phase 2: Non-ECMO respiratory support titration), and a trial of cessation of sweep gas flow (Phase 3: ECMO-Free Trial).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: All patients randomized to the Usual Care Group will undergo assessments of readiness for liberation, weaning, and decannulation at the discretion of the treatment team.
Study: NCT05251181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centhaquine
Description: Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock
Study: NCT06254911

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral Surgery with cervical lymphadenctomy (neck dissection)
Description: Undergo definitive surgical treatment to remove cancer from the tonsil or tongue base combined with removal of the at risk lymph nodes in the neck

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT04222673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Specialist Suicide Prevention
Description: The intervention will last 3-months, a time frame that overlaps with the typical duration of a VA suicide high risk flag. Meetings will be 30-45 minutes and occur primarily in the community, home, or by telephone. Session content will be rooted in Peer Specialists (PSs) offering nonjudgmental empathic support, active listening, and constructive disclosure and role modeling. A primary focus will be helping patients with flags to identify and strengthen connections with informal supports and participation in activities in their community that will enable them to feel more worthwhile as individuals and hopeful about their future.
Study: NCT06277895

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VOCs
Description: test the end-expiratory gas

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: VOCs
Description: test the end-expiratory gas
Study: NCT05358756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SACT-1
Description: Single administartion of 150mg SACT-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SACT-1
Description: Single administartion of 150mg SACT-1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EDURANT 25Mg Tablet
Description: Single administartion of six EDURANT 25mg tablets (Total 150mg)
Study: NCT04796051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neck orthosis - with posterior cervical weight
Description: The posterior cervical weight orthosis is made of a well-padded adjustable Velcro attached to the end with a two-kilogram weight attached with two durable straps. The device is firmly anchored around the curvature of the jaw and attached with Velcro to the apex of the skull.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep cervical flexors exercise
Description: The participant will lay down in crook lying position, participant's head relaxed on the flat surface. Each participant will passively tuck in his/her chin without activation of superficial cervical muscles. Participants of this group will do 15 repetitions x 3 sets of deep neck flexor exercises every day of the week.
Study: NCT05912777

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Scanner
Description: Scanner to be performed by patients
Study: NCT05774379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality and fatigue education
Description: virtual reality distraction for 3 days and fatigue education for children

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fatigue education
Description: fatigue education for children
Study: NCT04848558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Participants will receive IV infusion or SC injection of nipocalimab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Participants will receive IV infusion or SC injection of nipocalimab.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive IV infusion or SC injection of placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive IV infusion or SC injection of placebo.
Study: NCT05344794

Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme-linked immunosorbent assay
Description: Serum N/OFQ , IL-6 and NE levels were detected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme-linked immunosorbent assay
Description: Serum N/OFQ , IL-6 and NE levels were detected.
Study: NCT04995055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Investigational Multifocal Contact Lens TEST Lens
Description: TEST Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Investigational Multifocal Contact Lens TEST Lens
Description: TEST Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE® OASYS Multifocal
Description: CONTROL Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE® OASYS Multifocal
Description: CONTROL Lens
Study: NCT05380011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint Induced Movement Therapy and Bimanual Task Training
Description: Constraint-Induced Movement Therapy and Bimanual Task Training will be performed. Constraint-Induced Movement Therapy has been shown to improve the uni-manual capacity of the impaired limb as well as improvement in quality and efficiency of movement and greater grasp function, whereas Bimanual Task Training has been shown to improve bimanual task performance, bilateral spontaneous use of affected limb and better bimanual coordination during daily life activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bimanual Task Training
Description: Bimanual Task Training will be performed. Bimanual Task Training has been shown to improve bimanual task performance, bilateral spontaneous use of affected limb and better bimanual coordination during daily life activities.
Study: NCT05738473

Intervention type: DRUG
Intervention: antibiotic
Description: For pregnant women with GBS colonization, antibiotics are used to prevent infection
Study: NCT05675878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: This is a whole food, nutrient-dense diet that aims to remove exposure to specific food additives thought to have negative neurological effects, while also optimizing micronutrient intake.
Study: NCT05891925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audiobook App
Description: The intervention will consist of the use of the audiobook application (with poems) for 4 weeks. Here, the application will record the following data autonomously:~* older adult id,~* date, hour and time that the older adult listened to each poem,~* poems listened.~Initially, two questionnaires will be applied to the older adults: one to measure their digital skills (DIGCOMP), and another to assess their well-being prior to the experience with the audiobook application (Part A).~After two weeks of application use, a follow-up will be carried out, in order to answer any questions that may arise from the use of the application, and explain again the objectives of the research, if necessary. This follow-up will be initially done by telephone, and in person if required.~After four weeks, the older adult will be invited to a meeting at the Community Rehabilitation Center at Concepción, Chile, to answer the well-being questionnaire (Part B) and the usability questionnaire (SUS).
Study: NCT05354011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: Tape with a width of 5 cm and a thickness of 0.5 mm will be utilized. Kinesio Tex I Strip is estimated from elbow to fingertips and cut. It will be collapsed roughly two squares from the end and cut into two triangles on the overlay. The third and fourth fingers are fallen through openings and Kinesio Tex is applied on the dorsum of the hand with no strain. The situation of elbow extension, wrist extension, and radial deviation is given, and Kinesio Tex will be applied from hand to medial epicondyle with 15%-25% tension and end at medial epicondyle with no strain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Release Technique
Description: This group will receive Kinesiotaping with the same method along with Active release technique will be performed on group 2. We will apply profound tension at the region of tenderness while the patient is told to effectively move the injury site from a shortened to lengthened position. The setting of a contact point close to the injury and making the patient move in a way that creates a longitudinal sliding movement of delicate tissues e.g. nerves, ligaments and muscles underneath the contact point.
Study: NCT04927286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning to Breathe
Description: Learning to Breathe is an evidence-based mindfulness curriculum for adolescents

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Campus Connections
Description: Campus Connections is a mentoring program for at-risk adolescents
Study: NCT06433609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: Via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921
Description: Via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Via intravenous infusion
Study: NCT06392568

Intervention type: OTHER
Intervention: epidemiological records
Description: Healthcare associated infections due to emergent highly resistant bacteria, sites, risk factors, treatment and outcome
Study: NCT05650801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Therapy using a traditional music originally from Indonesian culture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Therapy using a traditional music originally from Indonesian culture
Study: NCT06442579

Intervention type: OTHER
Intervention: Walking on a treadmill
Description: Participants have to walk without holding handrails and without bodyweight support for at least 200 gait cycles. They are asked to walk at comfortable walking speed while watching forward to a screen without virtual reality projection. Arm should be next to the body to allow arm swing if possible.

Intervention type: OTHER
Intervention: Walking on a treadmill
Description: Participants have to walk without holding handrails and without bodyweight support for at least 200 gait cycles. They are asked to walk at comfortable walking speed while watching forward to a screen without virtual reality projection. Arm should be next to the body to allow arm swing if possible.